PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-93.01%
Negative net income growth while VET stands at 8.79%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-5.25%
Negative yoy D&A while VET is 12.50%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-73.27%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-522.22%
Negative yoy SBC while VET is 24.95%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-190.97%
Negative yoy working capital usage while VET is 19.33%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-190.97%
Negative yoy usage while VET is 19.33%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-72.92%
Both negative yoy, with VET at -306.35%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-62.50%
Both yoy CFO lines are negative, with VET at -2.50%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-43.31%
Negative yoy CapEx while VET is 27.28%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-243.86%
Both yoy lines negative, with VET at -200.00%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
43.31%
Purchases growth of 43.31% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
105.31%
Liquidation growth of 105.31% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-68.17%
Both yoy lines negative, with VET at -212.62%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-273.43%
We reduce yoy invests while VET stands at 5.24%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-8211.11%
Both yoy lines negative, with VET at -383.75%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.